Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 4412620160220010002
Clinical Hypertension
2016 Volume.22 No. 1 p.2 ~ p.2
Mesoglycan attenuates VSMC proliferation through activation of AMP-activated protein kinase and mTOR
Lee Kyung-Young

Lee Dong-Hyup
Choi Hyoung-Chul
Abstract
Background: Vascular smooth muscle cells (VSMC) proliferation contributes significantly to intimal thickening in atherosclerosis and restenosis diseases. Platelet derived growth factor (PDGF) has been implicated in VSMC proliferation
though the activation of multiple growth-promoting signals. Mesoglycan, a natural glycosaminoglycans preparation, is
reported to show vascular protective effect. However, the mechanisms by which mesoglycan inhibits proliferation of
VSMC are not fully understood. Here, we investigated whether mesoglycan exert therapeutic effect via AMP-activated
protein kinase (AMPK) and its underlying mechanism.

Methods: We cultured VSMC with increasing doses of mesoglycan. AMPK activation was measured by western blot analysis and cell proliferation was measured by flow cytometry.

Results: Mesoglycan dose- and time- dependently increased the phosphorylation of AMPK (Thr172) and its upstream
target, LKB1 (Ser428) and its downstream, ACC (Ser79) in VSMCs. Mesoglycan also blocked the PDGF-stimulated cell cycle progression through the G0/G1 arrest. AMPK DN¥á1, AMPK DN¥á2 or AMPK siRNA reduced the mesoglycan-mediated
inhibition of VSMC proliferation. AMPK signaling activated by mesoglycan regulates mTOR phosphorylation which
closely related to cell proliferation.

Conclusion: These data suggest that mesoglycan-induced AMPK activation suppress the VSMC proliferation via mTOR-dependent mechanism and mesoglycan may have beneficial effects on vascular proliferative disorders such as atherosclerosis.
KEYWORD
Mesoglycan, AMPK, VSMC, mTOR, Proliferation
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed